Comparative Pharmacology
Head-to-head clinical analysis: HEMADY versus TRASYLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEMADY versus TRASYLOL.
HEMADY vs TRASYLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEMADY is a phytonadione (vitamin K1) formulation that promotes hepatic synthesis of clotting factors II, VII, IX, and X, reversing anticoagulation by inhibiting vitamin K epoxide reductase.
Aprotinin is a serine protease inhibitor that forms reversible enzyme-inhibitor complexes with trypsin, plasmin, kallikrein, and chymotrypsin, thereby inhibiting fibrinolysis and reducing perioperative blood loss.
Adult: 5 mg orally twice daily.
1,000,000 KIU (kallikrein inhibitor units) IV loading dose over 10 minutes, followed by 250,000 KIU/hour continuous IV infusion during surgery; also 1,000,000 KIU added to cardiopulmonary bypass circuit prime volume.
None Documented
None Documented
Terminal elimination half-life is 1.2-2 hours in healthy adults; clinically relevant as it requires frequent dosing (every 4-6 hours) for sustained effect.
Terminal elimination half-life approximately 2 hours (alpha phase) and 10-12 hours (beta phase); prolongation in renal impairment.
Primarily renal excretion of unchanged drug (70-80%), with 20-30% metabolized and excreted as inactive metabolites in urine; less than 5% eliminated in feces via biliary secretion.
Primarily renal excretion; 70-80% of aprotinin is eliminated unchanged in urine within 48 hours; minor biliary/fecal elimination (<5%).
Category C
Category C
Antifibrinolytic
Antifibrinolytic